__NUXT_JSONP__("/drugs/Onilcamotide", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1164096-85-8",chebiId:b,chemicalFormula:b,definition:"A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.",fdaUniiCode:"UQE6KP7T0D",identifier:"C151937",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C1752"],synonyms:["ONILCAMOTIDE",a,"RV 001","RV 001V","RV001 Vaccine","RV001V","RhoC Peptide Vaccine RV001V"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FOnilcamotide",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Onilcamotide","","2021-10-30T13:33:29.023Z")));